Evaluation of the efficacy of subcutaneous immunotherapy with polymerised allergenic extract from Dermatophagoides pteronyssinus in patients with hypersensitivity to house dust mites
PROBELTE PHARMA has participated in the project entitled "EVALUATION OF THE EFFICACY OF SUBCUTANEOUSIMMUNOTHERAPY WITH POLYMERISED ALLERGENIC EXTRACT FROM DERMATOPHAGOIDES PTERONYSSINUS INPATIENTS WITH HYPERSENSITIVITY TO HOUSE DUST MITES" funded by the CDTI and the Ministry of Science and Innovation.
Specific immunotherapy with allergen extracts, known as "allergy shots", involves administering an "extract"
of the allergen responsible for the condition, with the aim of inducing the tolerance required to control
the allergic response. To date, it is considered the only treatment capable of altering the
natural course of the disease.
PROBELTE PHARMA has developed a safer allergen immunotherapy treatment based on an allergenic extract from a
house dust mite (Dermatophagoides pteronyssinus) that has been modified through polymerisation with
glutaraldehyde.
The MAIN objective of this research project was to assess the efficacy and safety of a polymerised extract from
D. pteronyssinus that was administered for 12 months to treat rhinoconjunctivitis (with or without asthma) caused by
hypersensitivity to D. pteronyssinus house dust mites in adult patients.
The project (file number IDI20190614C) was funded by the CENTER FOR THE DEVELOPMENTOF INDUSTRIAL TECHNOLOGY-PUBLIC CORPORATE ENTITY (CDTI-EPE) through the "Individual R&D Projects" call for proposals as part
of the Recovery, Transformation and Resilience Plan. The project was launched in March 2019 and ended in June 2023,
with a budget of €1,239,315.00 and a grant of €278,845.88.
